Nerio Therapeutics Inc. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) targeting moiety through a linker reported to be useful for the treatment of cancer, type 2 diabetes, obesity and metabolic diseases.
Ilab Co. Ltd. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer.
Daewoong Pharmaceutical Co. Ltd. has described transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease and cardiovascular disorders.
The treatment of hepatocellular carcinoma (HCC) has made progress due to immune checkpoint inhibitors (ICIs), but still many patients present innate or acquired resistance to ICIs, thus there is a need for the discovery of new therapeutic approaches for HCC treatment. Epigenetic alterations play a key role in liver cancer, so that they can suppress the expression of proteins involved in triggering the immune response against tumors. Spanish researchers have now identified a promising target for liver HCC treatment, named histone-lysine N-methyltransferase EHMT2, also known as protein G9a.
Protein palmitoylation is a post-translational modification catalyzed by a series of enzymes called zinc finger DHHC (ZDHHC) palmitoyltransferases. Scientists from Guangzhou Medical University and affiliated organizations aimed to assess the function of protein palmitoylation in renal fibrosis, a common pathway leading to end-stage chronic kidney disease.
A recent study published in Acta Neuropathologica Communications sheds light on the gender disparity in the incidence of ACTH-secreting pituitary neuroendocrine tumors (PitNETs), which occur more frequently in females than in males.
RSS
